Delivering a Diversified Long-term Revenue Stream

Fortress Biotech, Inc. is an innovative biopharmaceutical company focused on delivering a diversified, long-term revenue stream to our shareholders through the creation of a diverse portfolio of marketed products, as well as in-licensing opportunities and through the development of high-potential preclinical and clinical-stage product candidates. Fortress currently has five marketed products and over 25 programs in development.

Recent Event

Raymond James Human Health Innovation Conference

Latest Financial Results

$12.9M

Fortress’ net revenue totaled $12.9 million for the first quarter of 2020

$11.9M

Our five marketed specialty dermatology products generated first quarter 2020 net revenues of $11.9 million

$152.5M

Fortress’ consolidated cash, cash equivalents and restricted cash totaled $152.5 million

For complete information regarding our financials, see our periodic filings

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

mail icon

Sign Up for Email Alerts

Receive updates straight into your inbox

Sign up today

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was recently ranked number 10 in Deloitte’s 2019 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentage of fiscal year revenue growth over a three-year period.  Fortress is focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital and Nationwide Children’s Hospital.  For more information, visit www.fortressbiotech.com.

Fortress Biotech at a Glance

25+

Programs in Development

5

Marketed Products

Fortress Biotech Performance

Year over year company performance

As of Dec. 31, 2019 • 10-K 2019

Our Revenue-Generating Marketed Products

Investor Relations Contacts

Company

Fortress Biotech, Inc.
2 Gansevoort Street
9th Floor
New York, NY 10014
info@fortressbiotech.com

Investor Relations

Jaclyn Jaffe
T: 781-652-4500
ir@fortressbiotech.com

Bill Begien
T: 617-842-2222
bbegien@fortressbiotech.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
info@vstocktransfer.com
www.vstocktransfer.com